2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

622. Lymphomas: Translational – Non-Genetic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3527 Tumor and peripheral immunophenotyping in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B‑cell lymphoma (DLBCL) in the ELM‑2 study denotes histology-specific differences associated with response to odronextamab (Odro)

Matthew J Matasar, MD, MS, Aarin Jones, PhD2, Alan Chen, PhD3, Tae Min Kim, MD, PhD4, Stefano Luminari Sr, MD5, Nathalie Fiaschi6, Namita Gupta, PhD7, Seok-Goo Cho, MD, PhD8, Jose C Villasboas, MD9, Jurriaan Brouwer-Visser10
1 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
2 Regeneron Pharmaceuticals Inc., Tarrytown, New York, United States
3 Regeneron Pharmaceuticals Inc., Tarrytown, New York, United States
4 Seoul National University Hospital, Seoul, Korea, Rep. of South
5 Azienda Unità Sanitaria Locale – IRCCS of Reggio Emilia and University of Modena and Regio Emilia, Reggio Emilia and Modena, Italy
6 Regeneron Pharmaceuticals Inc., Tarrytown, New York, United States
7 Regeneron Pharmaceuticals Inc., Tarrytown, New York, United States
8 The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea, Rep. of South
9 Mayo Clinic, Rochester, Minnesota, United States
10 Regeneron Pharmaceuticals Inc., Tarrytown, New York, United States

Introduction 

Odro, a CD20×CD3 bispecific antibody (bsAb), had robust efficacy and a generally manageable safety profile in heavily pretreated patients (pts) with R/R B‑cell non-Hodgkin lymphoma (B‑NHL), including FL and DLBCL, in the Phase 2 ELM‑2 study (NCT03888105). FL and DLBCL have disparate clinical courses. This study assessed whether these 2 B-NHL subtypes also have distinct immunophenotypes, as well as the associations of intra-disease immunophenotypes with outcomes in ELM-2. 

Methods 

Pts in ELM-2 with R/R FL or DLBCL received intravenous Odro monotherapy with step-up dosing in Cycle 1. Subtype-specific dosing was described previously (Kim TM, et al. Ann Oncol 2024; Kim WS, et al. Nat Med 2025). Pts with complete response for ≥9 months switched to once every 4 weeks dosing.  

Baseline T-cell proximity in tumor biopsy samples was assessed by nearest-neighbor (k-d tree) Euclidean-distance queries using Python scripts on HALO-segmented cell centroids from multiplex immunofluorescence (mIF) images (0.325 µm/pixel), to identify T cells within bsAb engagement distance (0–20 µm from tumor cells). Immune profiling used flow cytometry of peripheral blood mononuclear cells and mIF of tumor biopsies. Expression of predefined immune-related genes was measured by bulk RNA sequencing.  

Results 

Focusing on the T cells within tumor biopsies, baseline spatial analysis showed a trend toward fewer CD8+ T cells within 0–20 µm of CD20+ B cells in pts with DLBCL (median 217 cells/mm2; IQR 27–851; n=35) vs FL (687 cells/mm2; IQR 93–1231; n=47). Overall T-cell infiltration was lower in DLBCL (n=41) vs FL (n=52) (median total T-cell density: 1527 [IQR 337–3281] vs 4332 [IQR 2226–6695] cells/mm2), driven by CD4+ T cells, notably helper T cells (752 [IQR 114–1541] vs 2808 [IQR 1710–4460] cells/mm2) and regulatory T cells (58 [IQR 4–200] vs 272 [IQR 105–536] cells/mm2).  

Peripheral T-cell differences were smaller but directionally consistent between DLBCL (n=175) and FL (n=96), with lower median counts for total T cells (542 [IQR 346–916] vs 636 [IQR 424–988] cells/µL), helper T cells (188 [IQR 116–288] vs 207 [IQR 152–344] cells/µL), and active regulatory T cells (7 [IQR 4–13; n=168] vs 12 [IQR 6–21; n=94] cells/µL). Tumor gene expression supported lower regulatory T-cell activity in DLBCL vs FL, with lower FOXP3, IL2, and CCR8 expression.  

In FL, pts with complete/partial response (responders) had a higher CD8+ T-cell density within the bsAb engagement distance vs non-responders (821 [IQR 171–1352; n=33] vs 83 [IQR 13–1083; n=10] cells/mm2). Progression-free survival (PFS) was numerically shorter in pts with FL who had low (<75th percentile) vs high (≥75th percentile) T-cell density within the engagement distance (median PFS: 19.15 months [95% CI, 11.99–27.83] vs 38.01 months [95% CI, 4.37–NA]; HR: 1.45 [0.61–3.46]).

Conclusions 

This study revealed that FL and DLBCL exhibited distinct T-cell immunophenotypes. FL is characterized by greater numbers of CD4+ T cells in tumor biopsies and peripheral blood, and a higher density of CD8+ T cells within engagement distance of tumor cells. In FL, having more CD8+ T cells near tumor cells (within the engagement distance) was numerically associated with improved outcomes, suggesting that spatial organization of effector cells influences response to Odro. Peripheral blood analyses showed DLBCL responders have “FL-like” T-cell populations, with increases in T cells, helper T cells, and regulatory T cells that directionally mirror differences between T-cell populations in FL and DLBCL. These findings highlight the likely involvement of spatial organization and immune composition in the response to Odro, and support further evaluation of candidate biomarkers, such as baseline CD8+ T cell–CD20+ B-cell proximity or peripheral regulatory T-cell activity, that may help identify pts most likely to benefit from Odro. 

 

Matthew J Matasar, MD, MS: Merck - Stock (publicly traded); Roche - Honoraria; Johnson & Johnson - Honoraria; Epizyme - Honoraria; AbbVie - Honoraria; Hutch-Med - Honoraria; Kite - Honoraria; Regeneron - Honoraria; AstraZeneca - Honoraria; ADC Therapeutics - Honoraria; Pfizer - Honoraria; Pharmacyclics - Research Funding; Genentech - Research Funding; Roche - Research Funding; Johnson & Johnson - Research Funding; Seattle Genetics - Research Funding; Bayer - Research Funding; DAVA Oncology - Consultancy (Includes expert testimony); Recursion Pharmaceuticals - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Lumanity - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Allogene - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Incyte Corporation - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Arnold & Porter - Consultancy (Includes expert testimony); Arvinas - Consultancy (Includes expert testimony); Visionaries - Consultancy (Includes expert testimony)